On April 7, 2023, KPMG China held the second "Biotechnology Innovation 50 Companies List Launch and Award Ceremony" in Beijing, Shanghai and Shenzhen offices, online and offline. After strict selection and evaluation by the expert panel, Leadtek was selected as one of the "KPMG China's 2nd Biotechnology Innovation 50 Companies List".

About "Biotechnology Innovation 50":

The 2nd "Biotech Innovation 50" is organized by KPMG China and co-organized by CITIC Securities Co. KPMG, together with more than ten internal and external authoritative experts, evaluates companies in six major fields, including biopharmaceuticals, cell therapy, gene therapy, in vitro diagnostics, medical devices and drug development, based on five core selection dimensions, including team, technology, product, market and financing, with open, fair and equitable evaluation criteria, and selects promising biotech innovative companies by combining field interviews and research of alternative companies by the judges. jointly promote the high-quality and healthy development of China's biotechnology innovation industry.

About Leadingtac

Founded in 2019, Leadingtac Bio is a biopharmaceutical company dedicated to the development of First-in-class/Best-in-class small molecule innovative drugs, with Targeted Protein Degradation (TPD) drug development platform with a focus on autoimmune and oncology, two therapeutic areas with great clinical unmet needs: autoimmune disease and oncology, providing breakthrough therapeutic solutions for patients. Located in Zhangjiang Science City, Shanghai, China, Leadingtac has nearly 1000 square meters of laboratory and office space, 20 employees, and has raised nearly CNY￥100 million in funding since its inception 3 years ago.